Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × regorafenib × 90 days × Clear all

Sponsor

Conditions

Colorectal Neoplasms 15 Carcinoma, Hepatocellular 4 Sarcoma, Ewing 3 Sarcoma 2 Glioblastoma 2 Esophageal Neoplasms 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Malignant Tumors 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Patient Compliance 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 MSI-H Colorectal Cancer 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liver Metastasis Colon Cancer 1 Leukemia, Myeloid, Acute 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 HER2-positive Colorectal Cancer 1

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡